Although there are studies on therapeutic targets against YFV, such as the Tripartite Motif Containing 56 (TRIM56) protein, which inhibits the initial replication of the virus through its E3 ubiquitin ligase activity, and the Transmembrane Protein 41B (TMEM41B), which interacts with viral proteins like NS4B, no approved medications are available for the specific treatment of yellow fever [11,12]. Here, TRIM56 is linked to viral infectious disease.